ClinicalTrials.gg
TerminatedNCT05623345Updated May 23, 2025Results posted

Psoriatic Arthritis Study of Izokibep

A Phase 2/3 interventional study of Izokibep and Placebo to izokibep in Psoriatic Arthritis, sponsored by ACELYRIN Inc.. Terminated at 71 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by ACELYRIN Inc. · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Enrollment
65th of 159
351 · median 228
Started
2022
with 10 others
Phase 2/3
2 of 194
none open now
Registered
148th of 194
by date

Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 65th largest by enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2022, is one of 2 in phase 2/3, and was the 148th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA).

This study will evaluate the efficacy of izokibep in subjects with PsA.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • psoriatic arthritis (PsA)
  • psoriasis
  • inflammatory arthritis
  • enthesitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General

  • Subject has provided signed including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Subject must be ≥18 (or the legal age of consent in the jurisdiction in which the study is taking place) and ≤75 years of age, at the time of signing the informed consent.

Type of Subject and Disease Characteristics

  • Clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to first dose of study drug and fulfillment of the ClASsification for Psoriatic ARthritis (CASPAR) criteria at Screening.
  • Active PsA defined as ≥3 tender joints (based on 68 joint counts) and ≥3 swollen joints (based on 66 joint counts) at Screening and Baseline Visits
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) negative at screening.
  • Subject must have had an inadequate response, intolerance, or to at least one of the following:

    1. nonsteroidal anti-inflammatory drug (NSAID)
    2. conventional-synthetic disease-modifying anti-rheumatic drugs (csDMARD) (i.e. methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, cyclosporine A)
    3. tumor necrosis factor-alpha inhibitor(s) (TNFi) (e.g. adalimumab, infliximab, etanercept, golimumab, certolizumab).
  • For subjects using methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, or apremilast, treated for ≥3 months and a stable dose (not to exceed 25 mg methotrexate per week, 20 mg leflunomide per day, sulfasalazine 3 g per day, hydroxychloroquine 400 mg per day, or apremilast 60 mg per day) for ≥4 weeks prior to first dose of study drug.
  • For subjects using , must have been on a stable dose and regimen and not to exceed 7.5 mg per day of prednisone (or other corticosteroid equivalent to 7.5 mg per day of prednisone) for ≥4 weeks prior to first dose of study drug.
  • Subjects using NSAIDs, or low potency opioid medications (tramadol, paracetamol in combination with hydrocodone or with codeine) must have been on a stable dose and regimen for ≥2 weeks prior to first dose of study drug.

Other Inclusions

  • No known history of active tuberculosis (TB).
  • Subject has a negative TB test at screening

Exclusion criteria

Exclusion Criteria:

Disease-related Medical Conditions

  • Any history or current confirmed diagnosis of inflammatory bowel disease (IBD)

OR

  • Any of the following symptoms (of unknown etiology) or any signs or symptoms within the last year that in the opinion of the Investigator may be suggestive of IBD, with fecal calprotectin ≥ 500 μg/g; OR if fecal calprotectin >150 to \<500 μg/g without confirmed approval from a GI consult that an IBD diagnosis is clinically unlikely when the following clinical signs and symptoms are present:

    1. prolonged or recurrent diarrhea
    2. prolonged or recurrent abdominal pain
    3. blood in stool
  • History of fibromyalgia, or any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including, but not limited to rheumatoid arthritis, gout, connective tissue diseases). Prior history of axial spondyloarthritis or fibromyalgia is permitted if documentation of change in diagnosis to PsA or documentation that the diagnosis was made incorrectly. Prior history of reactive arthritis or axial spondyloarthritis is permitted if an additional diagnosis of PsA is made. Chronic osteoarthritis symptoms that in the Investigator's opinion may interfere with study assessments.
  • Uncontrolled, system disease
  • within 5 years
  • Severe, uncontrolled, medically unstable mood disorder, such as severe depression.
  • History or evidence of any clinically significant disorder (including psychiatric), condition, or disease that, in the opinion of the investigator, may pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Active infection or history of certain infections
  • Candida infection requiring systemic treatment within 3 months prior to first dose of study drug.
  • Tuberculosis or fungal infection seen on available chest x-ray taken within 3 months prior to first dose of study drug or at screening (Exception: documented evidence of completed treatment and clinically resolved).
  • Known history of (HIV) or positive HIV test at screening.

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Group 1

    Placebo from Day 1/Week 0 to Week 15, then izokibep from Week 16 to Week 51

    Drug: Izokibep · Drug: Placebo to izokibep

  • Experimental
    Group 2

    Izokibep Dose 1 from Day 1/Week 0 to Week 51

    Drug: Izokibep

  • Experimental
    Group 3

    Izokibep Dose 2 from Day 1/Week 0 to Week 51

    Drug: Izokibep · Drug: Placebo to izokibep

  • Experimental
    Group 4

    Izokibep Dose 3 from Day 1/Week 0 to Week 51

    Drug: Izokibep · Drug: Placebo to izokibep

Interventions

  • Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)

  • DrugPlacebo to izokibep

    Form: Solution for injection Route of administration: Subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16

    ACR50 is a clinical trial measure for PsA, indicating a 50% improvement in symptoms. To qualify, participants must show a 50% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR50 is binary-patients either meet it or not.

    Time frame: Week 16

Secondary outcomes

  1. Number of Participants With Baseline ≥ 3% Body Surface Area (BSA) Psoriasis Who Achieved a 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI90) at Week 16

    PASI is a tool used in clinical trials to measure the severity and extent of psoriasis. Scores range from a minimum of 0 to a maximum of 72, with higher scores indicating more severe disease.

    Time frame: Baseline and Week 16

  2. Number of Participants With Baseline Enthesitis > 0 With Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) at Week 16

    LEI is a clinical tool used to assess enthesitis in conditions like psoriatic arthritis and spondyloarthritis. It evaluates six sites: bilateral lateral epicondyles, medial femoral condyles, and achilles tendons. Each site is scored 0 (no pain) or 1 (pain on pressure), with a total score ranging from a minimum of 0 to a maximum of 6, where higher scores indicate more severe enthesitis.

    Time frame: Baseline and Week 16

  3. Number of Participants Achieving Minimal Disease Activity (MDA) at Week 16

    A participants was classified as being in MDA when at least five of the following seven criteria were met: * Tender joint count based on 68 joints (TJC68) ≤ 1 * Swollen joint count based on 66 joints (SJC66) ≤ 1 * PASI ≤ 1 or BSA ≤ 3% * Participant's Pain Assessment (Visual Analogue Scale \[VAS\]) ≤ 15 mm * Participant's Global Activity VAS ≤ 20 mm (corresponding to participant's Global Assessment of Disease Activity) * Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 * Tender enthesitis points ≤ 1 out of 6 sites assessed by the LEI.

    Time frame: Week 16

  4. Number of Participants Achieving 20% Improvement in ACR (ACR20) at Week 16

    ACR20 is a clinical trial measure for PsA, indicating a 20% improvement in symptoms. To qualify, participants must show a 20% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR20 is binary-patients either meet it or not.

    Time frame: Week 16

  5. Number of Participants With Baseline Psoriatic Arthritis Impact of Disease (PsAID) Score ≥ 3 With Improvement in PsAID Score at Week 16

    The PsAID consists of nine items, each scored on a numeric rating scale (0-10), covering key aspects of disease burden, including pain, fatigue, skin problems, work/leisure activities, functional capacity, sleep disturbance, anxiety, coping, and social participation. The total score is calculated as a weighted sum of these individual items, with higher scores indicating a greater impact of the disease. The minimum score is 0 (no disease impact), while the maximum is 10 (worst possible disease impact). Reaching an improvement was considered an increase of 3 units from baseline score.

    Time frame: Week 16

  6. Change in Physical Function as Assessed by HAQ-DI From Baseline to Week 16

    The HAQ-DI consists of 20 questions divided into eight categories: dressing, arising, eating, walking, hygiene, reaching, grip, and other activities. Each item is scored on a scale from 0 to 3, where 0 = no difficulty, 1 = some difficulty, 2 = much difficulty, and 3 = unable to perform. The final HAQ-DI score is calculated as the average of the highest scores in each category, resulting in a range from 0 (no disability) to 3 (severe disability). Higher scores indicate greater functional impairment. A negative change indicates an improvement in functional impairment.

    Time frame: Baseline and Week 16

  7. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and AE of Special Interest During Period 1

    An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.

    Time frame: Up to Week 16, or 4 weeks after participant's last dose in case of treatment discontinuation

  8. Number of Participants Who Experienced TEAEs, Serious TEAEs and AE of Special Interest During Period 2

    An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.

    Time frame: First dose of study treatment on or after Week 16 up to Week 55

  9. Number of Participants With a Positive Treatment-emergent Anti-drug Antibody (ADA) Result

    Blood samples were collected at different timepoints throughout the study. ADA is considered "Positive" if any titer value is available.

    Time frame: Baseline to Week 65

07

Results

Posted May 23, 2025

Participant flow

A total of 351 participants with Psoriatic Arthritis (PsA) symptoms were recruited in Canada, United States, Bulgaria, Czech Republic, Germany, Hungary, Poland, and Spain between November 2022 and August 2024.

Participant flow — Overall Study
MilestonePeriod 1: Placebo QW ; Period 2: Izokibep 160 mg QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Started1188113112
Completed period 11148111105
Completed6445752
Not completed5445660
Withdrew: Withdrawal by subject140920
Withdrew: Lost to follow-up3072
Withdrew: Termination of study by sponsor3744038

Outcome measures

PrimaryNumber of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16

ACR50 is a clinical trial measure for PsA, indicating a 50% improvement in symptoms. To qualify, participants must show a 50% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR50 is binary-patients either meet it or not.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 161844945
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Cochran-Mantel-Haenszel · p = 0.0377 · Risk difference (rd): 36.22
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 27.69
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 24.44
SecondaryNumber of Participants With Baseline ≥ 3% Body Surface Area (BSA) Psoriasis Who Achieved a 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI90) at Week 16

PASI is a tool used in clinical trials to measure the severity and extent of psoriasis. Scores range from a minimum of 0 to a maximum of 72, with higher scores indicating more severe disease.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Number of Participants With Baseline ≥ 3% Body Surface Area (BSA) Psoriasis Who Achieved a 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI90) at Week 16
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Number of Participants With Baseline ≥ 3% Body Surface Area (BSA) Psoriasis Who Achieved a 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI90) at Week 16733738
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Cochran-Mantel-Haenszel · p = 0.0483 · Risk difference (rd): 43.71
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 46.15
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 52.80
SecondaryNumber of Participants With Baseline Enthesitis > 0 With Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) at Week 16

LEI is a clinical tool used to assess enthesitis in conditions like psoriatic arthritis and spondyloarthritis. It evaluates six sites: bilateral lateral epicondyles, medial femoral condyles, and achilles tendons. Each site is scored 0 (no pain) or 1 (pain on pressure), with a total score ranging from a minimum of 0 to a maximum of 6, where higher scores indicate more severe enthesitis.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
Number of Participants With Baseline Enthesitis > 0 With Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) at Week 16
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Number of Participants With Baseline Enthesitis > 0 With Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) at Week 163543830
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Cochran-Mantel-Haenszel · p = 0.0883 · Risk difference (rd): 32.26
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Cochran-Mantel-Haenszel · p = 0.2713 · Risk difference (rd): 9.19
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.8872 · Risk difference (rd): -1.20
SecondaryNumber of Participants Achieving Minimal Disease Activity (MDA) at Week 16

A participants was classified as being in MDA when at least five of the following seven criteria were met: * Tender joint count based on 68 joints (TJC68) ≤ 1 * Swollen joint count based on 66 joints (SJC66) ≤ 1 * PASI ≤ 1 or BSA ≤ 3% * Participant's Pain Assessment (Visual Analogue Scale \[VAS\]) ≤ 15 mm * Participant's Global Activity VAS ≤ 20 mm (corresponding to participant's Global Assessment of Disease Activity) * Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 * Tender enthesitis points ≤ 1 out of 6 sites assessed by the LEI.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Achieving Minimal Disease Activity (MDA) at Week 16
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Number of Participants Achieving Minimal Disease Activity (MDA) at Week 161734746
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Cochran-Mantel-Haenszel · p = 0.1654 · Risk difference (rd): 23.45
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 26.58
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 25.84
SecondaryNumber of Participants Achieving 20% Improvement in ACR (ACR20) at Week 16

ACR20 is a clinical trial measure for PsA, indicating a 20% improvement in symptoms. To qualify, participants must show a 20% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR20 is binary-patients either meet it or not.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants Achieving 20% Improvement in ACR (ACR20) at Week 16
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Number of Participants Achieving 20% Improvement in ACR (ACR20) at Week 164167266
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Cochran-Mantel-Haenszel · p = 0.0106 · Risk difference (rd): 43.09
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 28.46
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = 0.0002 · Risk difference (rd): 23.70
SecondaryNumber of Participants With Baseline Psoriatic Arthritis Impact of Disease (PsAID) Score ≥ 3 With Improvement in PsAID Score at Week 16

The PsAID consists of nine items, each scored on a numeric rating scale (0-10), covering key aspects of disease burden, including pain, fatigue, skin problems, work/leisure activities, functional capacity, sleep disturbance, anxiety, coping, and social participation. The total score is calculated as a weighted sum of these individual items, with higher scores indicating a greater impact of the disease. The minimum score is 0 (no disease impact), while the maximum is 10 (worst possible disease impact). Reaching an improvement was considered an increase of 3 units from baseline score.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With Baseline Psoriatic Arthritis Impact of Disease (PsAID) Score ≥ 3 With Improvement in PsAID Score at Week 16
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Number of Participants With Baseline Psoriatic Arthritis Impact of Disease (PsAID) Score ≥ 3 With Improvement in PsAID Score at Week 161234340
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Cochran-Mantel-Haenszel · p = 0.1147 · Risk difference (rd): 30.15
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 29.04
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Cochran-Mantel-Haenszel · p = <.0001 · Risk difference (rd): 24.99
SecondaryChange in Physical Function as Assessed by HAQ-DI From Baseline to Week 16

The HAQ-DI consists of 20 questions divided into eight categories: dressing, arising, eating, walking, hygiene, reaching, grip, and other activities. Each item is scored on a scale from 0 to 3, where 0 = no difficulty, 1 = some difficulty, 2 = much difficulty, and 3 = unable to perform. The final HAQ-DI score is calculated as the average of the highest scores in each category, resulting in a range from 0 (no disability) to 3 (severe disability). Higher scores indicate greater functional impairment. A negative change indicates an improvement in functional impairment.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Score on scale
Change in Physical Function as Assessed by HAQ-DI From Baseline to Week 16
Score on scalePeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Change in Physical Function as Assessed by HAQ-DI From Baseline to Week 16-0.14 (-0.23 to -0.06)-0.03 (-0.35 to 0.28)-0.30 (-0.39 to -0.21)-0.31 (-0.40 to -0.22)
Statistical analysis
  • Period 1: Placebo QW vs Izokibep 80 mg Q4W · Mixed model repeated measures analysis · p = 0.514 · Ls mean difference: 0.11 · 95% CI -0.22 to 0.44
  • Period 1: Placebo QW vs Izokibep 160 mg Q2W · Mixed model repeated measures analysis · p = 0.010 · Ls mean difference: -0.16 · 95% CI -0.28 to -0.04
  • Period 1: Placebo QW vs Izokibep 160 mg QW · Mixed model repeated measures analysis · p = 0.006 · Ls mean difference: -0.17 · 95% CI -0.29 to -0.05
SecondaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and AE of Special Interest During Period 1

An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.

Time frame:
Up to Week 16, or 4 weeks after participant's last dose in case of treatment discontinuation
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and AE of Special Interest During Period 1
ParticipantsPeriod 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
TEAEs4867682
Serious TEAEs1223
AEs of Special Interest2156
SecondaryNumber of Participants Who Experienced TEAEs, Serious TEAEs and AE of Special Interest During Period 2

An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.

Time frame:
First dose of study treatment on or after Week 16 up to Week 55
Reported as:
Count of participants · Participants
Number of Participants Who Experienced TEAEs, Serious TEAEs and AE of Special Interest During Period 2
ParticipantsPeriod 2: Placebo/Izokibep 160 mg QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
TEAEs8956767
Serious TEAEs4172
AEs of Special Interest3152
SecondaryNumber of Participants With a Positive Treatment-emergent Anti-drug Antibody (ADA) Result

Blood samples were collected at different timepoints throughout the study. ADA is considered "Positive" if any titer value is available.

Time frame:
Baseline to Week 65
Reported as:
Count of participants · Participants
Number of Participants With a Positive Treatment-emergent Anti-drug Antibody (ADA) Result
ParticipantsPeriod 1: Placebo QW; Period 2: Izokibep 160 mg QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Baseline5645754
Week 25636154
Week 45645855
Week 125325551
Week 165465757
Week 244057075
Week 366276776
Week 526576368
Follow-up Visit - Week 597666777
End of Study - Week 654923140

Adverse events

Collected over For Placebo QW - Period 1: Up to Week 16, or 4 weeks after participant's last dose in case of treatment discontinuation. A TEAE that occurred before the first dose of study drug in Period 2 and is within 28 days after the end of study drug in Period 1 is assigned to Period 1. For Placebo/Izokibep 160 mg QW - Period 2: From Week 16 up to Week 55. For Izokibep 80 mg Q4W, Izokibep 160 mg Q2W, Izokibep 160 mg QW: Up to Week 55.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QW - Period 10/118 (0%)1/118 (0.8%)9/118 (7.6%)
Placebo/Izokibep 160 mg QW - Period 20/114 (0%)4/114 (3.5%)65/114 (57%)
Izokibep 80 mg Q4W0/8 (0%)2/8 (25%)6/8 (75%)
Izokibep 160 mg Q2W0/113 (0%)8/113 (7.1%)78/113 (69%)
Izokibep 160 mg QW0/112 (0%)4/112 (3.6%)84/112 (75%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPlacebo QW - Period 1Placebo/Izokibep 160 mg QW - Period 2Izokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Angina unstableCardiac disorders0/1180/1141/80/1130/112
Coronary artery diseaseCardiac disorders0/1180/1141/80/1130/112
Supraventricular tachycardiaCardiac disorders0/1180/1141/80/1130/112
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1180/1141/80/1130/112
Atrial fibrillationCardiac disorders0/1180/1140/81/1131/112
InflammationGeneral disorders0/1180/1140/80/1131/112
Systemic inflammatory response syndromeGeneral disorders0/1180/1140/80/1131/112
CellulitisInfections and infestations0/1180/1140/80/1131/112
PneumoniaInfections and infestations0/1180/1140/80/1131/112
Hepatic enzyme increasedInvestigations0/1180/1140/80/1131/112
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlacebo QW - Period 1Placebo/Izokibep 160 mg QW - Period 2Izokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QW
Injection site erythemaGeneral disorders0/11853/1142/852/11365/112
Injection site pruritusGeneral disorders1/11827/1142/825/11329/112
Upper respiratory tract infectionInfections and infestations4/1186/1142/810/11320/112
NasopharyngitisInfections and infestations0/11814/1140/818/11313/112
Coronary artery diseaseCardiac disorders0/1180/1141/80/1130/112
Angina unstableCardiac disorders0/1180/1141/80/1130/112
Supraventricular tachycardiaCardiac disorders0/1180/1141/80/1130/112
DiarrhoeaGastrointestinal disorders0/1187/1141/84/1133/112
Tooth disorderGastrointestinal disorders0/1180/1141/80/1130/112
Injection site swellingGeneral disorders0/11813/1141/813/11313/112

Baseline characteristics

Full Analysis Set: all participants randomized who received at least one administration of test material was included in the summaries and analyses.

Age, Continuous
Age, Continuous(Years)Period 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QWTotal
Mean52.6 ± 11.7463.1 ± 9.4049.5 ± 13.2651.8 ± 12.2051.6 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)Period 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QWTotal
Female6754648166
Male5136764185
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Period 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QWTotal
Hispanic or Latino13114735
Not Hispanic or Latino105799104315
Unknown or Not Reported00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Period 1: Placebo QWIzokibep 80 mg Q4WIzokibep 160 mg Q2WIzokibep 160 mg QWTotal
American Indian or Alaska Native00000
Asian30216
Native Hawaiian or Other Pacific Islander00000
Black or African American30227
White1108108109335
More than one race00000
Other20103
08

Study locations

71 sites
  • Clinical Research Site
    Flagstaff, Arizona 86001, United States
  • Clinical Research Site
    Glendale, Arizona 85306, United States
  • Clinical Research Site
    Mesa, Arizona 85210, United States
  • Clinical Research Site
    Phoenix, Arizona 85037, United States
  • Clinical Research Site
    Tucson, Arizona 85704, United States
  • Clinical Research Site
    Jonesboro, Arkansas 72401, United States
  • Clinical Research Site
    Encino, California 91436, United States
  • Clinical Research Site
    Fountain Valley, California 92708, United States
  • Clinical Research Site
    Fullerton, California 92835, United States
  • Clinical Research Site
    Los Angeles, California 90045, United States
  • Clinical Research Site
    Rancho Mirage, California 92270, United States
  • Clinical Research Site
    Sacramento, California 95815, United States
  • Clinical Research Site
    San Diego, California 92128, United States
  • Clinical Research Site
    Santa Monica, California 90404, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Aventura, Florida 33180, United States
  • Clinical Research Site
    Clearwater, Florida 33765, United States
  • Clinical Research Site
    Kissimmee, Florida 34741, United States
  • Clinical Research Site
    New Port Richey, Florida 34652, United States
  • Clinical Research Site
    Ormond Beach, Florida 32714, United States
  • Clinical Research Site
    Sarasota, Florida 34239-6900, United States
  • Clinical Research Site
    Gainesville, Georgia 30501, United States
  • Clinical Research Site
    Hinsdale, Illinois 60521, United States
  • Clinical Research Site
    Orland Park, Illinois 60467, United States
  • Clinical Research Site
    Skokie, Illinois 60076, United States
  • Clinical Research Site
    Lexington, Kentucky 40504, United States
  • Clinical Research Site
    Grand Blanc, Michigan 48439, United States
  • Clinical Research Site
    Kalispell, Montana 59901, United States
  • Clinical Research Site
    Santa Fe, New Mexico 87505, United States
  • Clinical Research Site
    Hickory, North Carolina 28602, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Corvallis, Oregon 97330, United States
  • Clinical Research Site
    Duncansville, Pennsylvania 16635-8445, United States
  • Clinical Research Site
    Jackson, Tennessee 38305, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    Colleyville, Texas 76034, United States
  • Clinical Research Site
    Irving, Texas 75013, United States
  • Clinical Research Site
    Mesquite, Texas 75150, United States
  • Clinical Research Site
    Seattle, Washington 98122, United States
  • Clinical Research Site
    Beckley, West Virginia 25801, United States
  • Clinical Research Site
    Bourgas, 8000, Bulgaria
  • Clinical Research Site
    Pleven, 5808, Bulgaria
  • Clinical Research Site
    Ruse, 7012, Bulgaria
  • Clinical Research Site
    Sofia, 1303, Bulgaria
  • Clinical Research Site
    Sydney, Nova Scotia B1S 3N1, Canada
  • Clinical Research Site
    Windsor, Ontario N8X 1T3, Canada
  • Clinical Research Site
    Québec, Quebec G1V 3M7, Canada
  • Clinical Research Site
    Trois-Rivières, Quebec G8Z 1Y2, Canada
  • Clinical Research Site
    Saskatoon, Saskatchewan S7H 5M7, Canada
  • Clinical Research Site
    Ostrava, 702 00, Czechia
  • Clinical Research Site
    Praha, 140 00, Czechia
  • Clinical Research Site
    Zlin, 760 01, Czechia
  • Clinical Research Site
    Frankfurt am Main, 60590, Germany
  • Clinical Research Site
    Hamburg, 20095, Germany
  • Clinical Research Site
    Budapest, 1027, Hungary
  • Clinical Research Site (003)
    Budapest, 1036, Hungary
  • Clinical Research Site
    Kalocsa, 6300, Hungary
  • Clinical Research Site
    Székesfehérvár, 8000, Hungary
  • Clinical Research Site
    Veszprém, 8200, Hungary
  • Clinical Research Site
    Bialystok, 15-351, Poland
  • Clinical Research Site
    Białystok, 15-077, Poland
  • Clinical Research Site
    Bydgoszcz, 85-650, Poland
  • Clinical Research Site
    Elbląg, 82-300, Poland
  • Clinical Research Site
    Kraków, 30-510, Poland
  • Clinical Research Site
    Poznań, 00-874, Poland
  • Clinical Research Site
    Poznań, 61-113, Poland
  • Clinical Research Site
    Warszawa, 00-874, Poland
  • Clinical Research Site
    Warszawa, 02-691, Poland
  • Clinical Research Site
    Alcobendas, 28100, Spain
  • Clinical Research Site
    Santiago De Compostela, 15702, Spain
  • Clinical Research Site
    Sevilla, 41010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Nov 2023, 12 months.

Results were first posted in May 2025, 1 year 5 months after primary completion. A results delay was requested in Nov 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2022
First posted
Nov 21, 2022
StartActual
Nov 21, 2022
Primary completionActual
Nov 30, 2023
CompletionActual
Aug 8, 2024
Results delay requested
Nov 25, 2024
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05623345
Lead sponsor
ACELYRIN Inc.
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Nov 21, 2022
Primary completion
Nov 30, 2023
Completion
Aug 8, 2024
Results posted
May 23, 2025
Last update
May 23, 2025

Study contacts

Shepard Mpofu, MD, Clinical Development
study director · ACELYRIN Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izokibep

Start the discussion